| Jun 23 |
Cogent Biosciences: Inflection Year Directly Ahead
|
| Jun 14 |
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
|
| May 24 |
Cogent Bio spikes after updating late-stage data for lead asset
|
| May 23 |
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
|
| May 23 |
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
|
